<DOC>
	<DOCNO>NCT01050985</DOCNO>
	<brief_summary>This study people advance cancer curative treatment exist . The purpose study test safety effectiveness combination drug Temsirolimus Capecitabine see effect cancer . Temsirolimus drug give vein target protein important growth cancer cell know mTOR . By inhibit protein , Temsirolimus inhibit cancer cell growth even lead death . Capecitabine traditional chemotherapy . It oral pill get convert body common chemotherapy know 5-fluorouracil . This research do know combination Temsirolimus Capecitabine work well Capecitabine Temsirolimus alone .</brief_summary>
	<brief_title>A Study Temsirolimus Plus Capecitabine Patients With Advanced Cancer</brief_title>
	<detailed_description>This Phase I study design assess safety clinical activity temsirolimus combination capecitabine patient advanced malignancy . Because toxicity capecitabine well establish , base previous clinical trial temsirolimus continuous infusion 5-fluorouracil , alternate dose escalation plan employ . The first stage study perform identify maximally tolerate dose combination , capecitabine give every 2 week schedule . The start dose temsirolimus 15-mg IV day 1 8 plus capecitabine 1000 mg/m2 mouth twice day day 1-7 14 day schedule . Patients enrol standard 3+3 dose escalate fashion maximum dose temsirolimus 25-mg maximum dose capecitabine 1750 mg/m2 twice day . If maximally tolerate dose determine every 2 week schedule , second stage study similar dose escalation plan employ every 3 week schedule .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologically proven adenocarcinoma measurable evaluable disease Disease capecitabine approve compendia list Advanced unresectable , and/or metastatic disease know curative therapy Performance status 02 Adequate hepatic , bone marrow , renal function Brain metastasis control least 3 month Active severe infection know chronic infection HIV , hepatitis B virus , hepatitis C virus Cardiovascular disease problem include unstable angina , therapy lifethreatening ventricular arrhythmia , myocardial infarction , stroke , congestive heart failure within last 6 month Lifethreatening visceral disease severe concurrent disease Women pregnant breastfeeding Anticipated patient survival 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>advanced cancer</keyword>
	<keyword>temsirolimus</keyword>
	<keyword>capecitabine</keyword>
</DOC>